- Company to Host Pulmonary R&D Day on May 26, 2022 PASADENA, Calif. --(BUSINESS WIRE)--Mar. 24, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MUC5AC, the company’s investigational

PASADENA, Calif. --(BUSINESS WIRE)--Mar. 15, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce

- Topline data expected in the first half of 2023 PASADENA, Calif. --(BUSINESS WIRE)--Feb. 24, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES -2 clinical study of ARO-ANG3, the

PASADENA, Calif. --(BUSINESS WIRE)--Feb. 18, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production

PASADENA, Calif. --(BUSINESS WIRE)--Feb. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a

- Conference Call and Webcast Today, February 2, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 2, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021 .

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 24, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline (LSE/NYSE: GSK) announced on November 22, 2021 , has now closed.

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 21, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021 .

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 12, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI , which is planned to be the site of an approximately 140,000 square foot